Debiopharm Group

Debiopharm, TCG Lifesciences collaborate to develop antibiotics

Monday, September 9, 2013 03:51 PM

Debiopharm Group, a Swiss-based global biopharmaceutical company focused on development of prescription drugs that target unmet medical needs and companion diagnostics, and TCG Lifesciences, a CRO in early drug discovery and development, have inked an exclusive discovery collaboration to develop antibiotics targeting drug-resistant bacteria for community hospital-acquired infections.

More... »

Cenix BioScience, Debiopharm Group to identify predictive biomarkers

Wednesday, May 29, 2013 10:47 AM

Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a global Swiss biopharmaceutical group of companies focused on prescription drugs that target unmet medical needs, including oncology and companion diagnostics, have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

More... »

Shasun, Debiopharm Group ink licensing agreement for Huperzine-A

Wednesday, April 17, 2013 10:46 AM

Shasun Pharmaceuticals, a global pharmaceutical contracting organization, and Debiopharm Group, a Swiss-based global biopharmaceutical group focused on unmet medical needs, entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

More... »

Debiopharm, Ascenta ink exclusive license agreement

Wednesday, September 7, 2011 11:11 AM

Debiopharm Group and Ascenta Therapeutics have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.

More... »

INC Research forms partnership with Debiopharm Group

Wednesday, July 27, 2011 01:25 PM

INC Research, a therapeutically focused CRO, and Debiopharm Group, a Swiss-based global biopharmaceutical group, have formed a strategic partnership.

More... »

Debiopharm names management team

Wednesday, July 20, 2011 11:32 AM

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies, has named a number of management figures to key positions.

More... »